Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents

To date, few studies have systematically evaluated the most appropriate location for grafting catechoiaminergic cells as a potential treatment for Parkinson's disease (PD). The following study was conducted to determine 1) if placement of catecholamine-secreting encapsulated PC12 cells into the...

Full description

Bibliographic Details
Main Authors: Dwaine F. Emerich, Shelley R. Winn, Mark D. Lindner
Format: Article
Language:English
Published: SAGE Publishing 1996-09-01
Series:Cell Transplantation
Online Access:https://doi.org/10.1177/096368979600500508
_version_ 1818323160976588800
author Dwaine F. Emerich
Shelley R. Winn
Mark D. Lindner
author_facet Dwaine F. Emerich
Shelley R. Winn
Mark D. Lindner
author_sort Dwaine F. Emerich
collection DOAJ
description To date, few studies have systematically evaluated the most appropriate location for grafting catechoiaminergic cells as a potential treatment for Parkinson's disease (PD). The following study was conducted to determine 1) if placement of catecholamine-secreting encapsulated PC12 cells into the lateral ventricle of 6-OHDA–treated rats is as effective as intrastriatal implants on reducing apomorphine-induced rotational behavior, and 2) to determine if the survival of encapsulated PC12 cells is differentially affected by the implant site. Polymer-encapsulated PC12 cells were implanted into either the striatum or lateral ventricle of unilateral 6-OHDA–lesioned rats. Animals were tested for apomorphine-induced rotations over a 6-wk period. Only those animals that received intrastriatal implants of encapsulated PC12 cells showed a reduction in rotation behavior. Moreover, removal of the devices from the striatum resulted in a return to preimplant rotation levels. Postexplant neurochemical analyses demonstrated that the potassium-evoked l-dopa device output increased in vivo while the potassium-evoked dopamine output from the devices decreased over time in vivo. The location of the implant significantly affected catecholamine output from the PC12 cell-loaded devices. The increase in potassium-evoked l-dopa output was greatest, as was the decrease in potassium-evoked dopamine output, from those devices implanted in the striatum. Basal output of dopamine and DOPAC was also significantly higher from devices explanted from the lateral ventricle. These results demonstrate that the continued presence of intrastriatal implants of encapsulated PC12 cells is required to maintain the behavioral effects in 6-OHDA–lesioned rats. In addition, the site of implantation appears to affect device output. These results provide additional support for intraparenchymal delivery of l-dopa and dopamine via polymer encapsulation as a possible treatment for PD.
first_indexed 2024-12-13T11:08:17Z
format Article
id doaj.art-aed3786d481d4690ac94f94b96f5beb2
institution Directory Open Access Journal
issn 0963-6897
1555-3892
language English
last_indexed 2024-12-13T11:08:17Z
publishDate 1996-09-01
publisher SAGE Publishing
record_format Article
series Cell Transplantation
spelling doaj.art-aed3786d481d4690ac94f94b96f5beb22022-12-21T23:48:54ZengSAGE PublishingCell Transplantation0963-68971555-38921996-09-01510.1177/096368979600500508Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian RodentsDwaine F. Emerich0Shelley R. Winn1Mark D. Lindner2CytoTherapeutics, Inc., 2 Richmond Square, Providence, RI 02906, USACytoTherapeutics, Inc., 2 Richmond Square, Providence, RI 02906, USACytoTherapeutics, Inc., 2 Richmond Square, Providence, RI 02906, USATo date, few studies have systematically evaluated the most appropriate location for grafting catechoiaminergic cells as a potential treatment for Parkinson's disease (PD). The following study was conducted to determine 1) if placement of catecholamine-secreting encapsulated PC12 cells into the lateral ventricle of 6-OHDA–treated rats is as effective as intrastriatal implants on reducing apomorphine-induced rotational behavior, and 2) to determine if the survival of encapsulated PC12 cells is differentially affected by the implant site. Polymer-encapsulated PC12 cells were implanted into either the striatum or lateral ventricle of unilateral 6-OHDA–lesioned rats. Animals were tested for apomorphine-induced rotations over a 6-wk period. Only those animals that received intrastriatal implants of encapsulated PC12 cells showed a reduction in rotation behavior. Moreover, removal of the devices from the striatum resulted in a return to preimplant rotation levels. Postexplant neurochemical analyses demonstrated that the potassium-evoked l-dopa device output increased in vivo while the potassium-evoked dopamine output from the devices decreased over time in vivo. The location of the implant significantly affected catecholamine output from the PC12 cell-loaded devices. The increase in potassium-evoked l-dopa output was greatest, as was the decrease in potassium-evoked dopamine output, from those devices implanted in the striatum. Basal output of dopamine and DOPAC was also significantly higher from devices explanted from the lateral ventricle. These results demonstrate that the continued presence of intrastriatal implants of encapsulated PC12 cells is required to maintain the behavioral effects in 6-OHDA–lesioned rats. In addition, the site of implantation appears to affect device output. These results provide additional support for intraparenchymal delivery of l-dopa and dopamine via polymer encapsulation as a possible treatment for PD.https://doi.org/10.1177/096368979600500508
spellingShingle Dwaine F. Emerich
Shelley R. Winn
Mark D. Lindner
Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
Cell Transplantation
title Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
title_full Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
title_fullStr Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
title_full_unstemmed Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
title_short Continued Presence of Intrastriatal but not Intraventricular Polymer-Encapsulated PC12 Cells is Required for Alleviation of Behavioral Deficits in Parkinsonian Rodents
title_sort continued presence of intrastriatal but not intraventricular polymer encapsulated pc12 cells is required for alleviation of behavioral deficits in parkinsonian rodents
url https://doi.org/10.1177/096368979600500508
work_keys_str_mv AT dwainefemerich continuedpresenceofintrastriatalbutnotintraventricularpolymerencapsulatedpc12cellsisrequiredforalleviationofbehavioraldeficitsinparkinsonianrodents
AT shelleyrwinn continuedpresenceofintrastriatalbutnotintraventricularpolymerencapsulatedpc12cellsisrequiredforalleviationofbehavioraldeficitsinparkinsonianrodents
AT markdlindner continuedpresenceofintrastriatalbutnotintraventricularpolymerencapsulatedpc12cellsisrequiredforalleviationofbehavioraldeficitsinparkinsonianrodents